Smoking cessations are drugs and therapies used in the treatment of withdrawal symptoms associated with the cessation of nicotine. Nicotine use is a risk factor for many diseases and disorders including cardiovascular diseases, cancer, etc. Green tobacco sickness, caused by nicotine absorption through the skin by the handling of wet tobacco leaves in the tobacco industry is also a concern especially among children. Awareness about these health hazards has influenced individuals to adopt smoking cessation therapy. Awareness through television advertisements, information brochures, newspapers, and other media has proved to be effective in curbing the nicotine addiction crisis to some extent.
The global smoking cessation market is expected to reach over USD xx billion by 2026. The other market driving factors include increasing desire and drives to quit smoking and active role of social and health organizations against tobacco use, the prohibitive costs due to high taxes leveraged on tobacco products, social stigma imposed on tobacco users, etc. The other critical market-driving factor is the huge number of unmet needs. The World Health Organization (WHO), estimates around 1,100 million smokers worldwide with emerging economies accounting for about 70% of the global smoker population.
Currently, the FDA has approved numerous NRT products, as well as other prescription drugs, for smoking cessation. Specifically, the FDA has approved three types of over-the-counter NRTs–nicotine gum, transdermal nicotine patch, and nicotine lozenge, and two types of prescription NRTs-nicotine nasal spray and nicotine inhaler. There are no products of electronic nicotine delivery system (ENDS) currently approved for use as an NRT for smoking cessation. ENDSs available today, including e-cigarettes and personal vaporizers, are marketed only for recreational use and thus are regulated by FDA as tobacco products. ENDS marketing as a smoking cessation tool with smoking cessation claims has to require FDA premarket approval as a “drug.”
The increase in the desire to quit smoking and the numerous health complications associated with smoking act as strong incentives for companies for introducing novel smoking cessation products, such as Revolymer, which has entered the next generation nicotine gums for helping smokers to quit smoking. The launching of these improved and innovative nicotine replacement therapy products is to serve as an important impact-rendering driver for the growth of the smoking cessation market.
The growth in the incidence of target diseases like chronic obstructive pulmonary disease (COPD), asthma, cardiac diseases, and lung cancer, and the increasing awareness about the hazardous side effects of smoking are the factors anticipated to promote the expansion of the market. Educational institutions are remaining active in organizing various campaigns and programs to spread information about the harmful effects and consequences of smoking to increase young population awareness. The market players are showing slow and steady progress in the e-cigarette market by keeping the focus on developing, commercializing, and distributing the nicotine products that are FDA approved. For example, in 2014, Victory Electronic Cigarettes Corporation acquired Ten Motives Ltd. with an aim to expand its distribution channels and attain broader market coverage.
The global smoking cessation market is segmented on the basis of Product and Region.
Based on the product:
Nicotine Replacement Therapy (NRT) is dominating the smoking cessation market owing to Increased availability and the introduction of the ingestible nicotine products having different flavors. The e-cigarette segment is expected to grow at a significant rate over the forecast period owing to introducing second and third generation e-cigarettes, the presence of numerous vendors operating and selling e-cigarettes under different brand names, and the availability of various flavored products.
Based on the region: North America, Europe, Asia Pacific, Latin America, and MEA.
North America holds the largest market share due to the increasing awareness levels of various products for, e.g. around 90% of the U.S. population was identified as aware of e-cigarettes. The Asia Pacific is known to be the fastest growing market. The registration of novel products and e-cigarettes, and the strengthening of the company distribution channels in countries, including China, India, and Australia, are anticipated for the market growth over the forecast period.
The key players of Global smoking cessation market include Pfizer, Inc., Cipla Ltd., Novartis International AG, Takeda Pharmaceutical Company Ltd., McNeil AB, GlaxoSmithKline plc, Imperial Tobacco Ltd., Revolymer plc, VMR Products, LLC, and others.
Report Description: The report covers in-depth analysis of the Global Smoking Cessation Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), By Product (inhaler, lozenge, sublingual tablet, spray, patch, others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in the Global Smoking Cessation Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.